MCM
IBB icon

MAI Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

MAI Capital Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-400
Closed -$60K – 821
2021
Q1 		$60K Buy
+400
New +$63.5K ﹤0.01% 708

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

MAI Capital Management's IBB Position: Q1 2026 in Review

MAI Capital Management increased its iShares Biotechnology ETF (IBB) stake by 1.7% in Q1 2026, buying an estimated $234K and bringing the position to 81,832 shares worth $13.8M. The position accounts for 0.08% of the portfolio, ranked #224.

MAI Capital Management first reported a position in IBB in Q2 2015 and has held it in 35 quarters since. 920 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

  • MAI Capital Management held 81,832 shares of iShares Biotechnology ETF worth $13.8M as of Q1 2026.
  • MAI Capital Management bought 1,371 iShares Biotechnology ETF shares in Q1 2026, an estimated $234K.
  • iShares Biotechnology ETF made up 0.08% of MAI Capital Management's portfolio in Q1 2026, its #224 holding.
  • MAI Capital Management first reported a position in iShares Biotechnology ETF in Q2 2015 and has held it in 35 quarters since.
  • 920 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.